

# CAMEROON

Number of new cases

**19 564**

Number of deaths


**12 798**

Number of prevalent cases (5-year)

**43 618**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	13 964 025	13 947 519	27 911 544
<b>Incidence*</b>			
Number of new cancer cases	7 986	11 578	19 564
Age-standardized incidence rate	113.3	139.9	126.0
Risk of developing cancer before the age of 75 years (cum. risk %)	12.1	14.3	13.1
Top 3 leading cancers (ranked by cases)**	Prostate Kaposi sarcoma NHL	Breast Cervix uteri NHL	Breast Cervix uteri Prostate
<b>Mortality*</b>			
Number of cancer deaths	5 312	7 486	12 798
Age-standardized mortality rate	79.7	95.8	87.3
Risk of dying from cancer before the age of 75 years (cum. risk %)	8.4	10.3	9.4
Top 3 leading cancers (ranked by deaths)**	Prostate Liver Kaposi sarcoma	Breast Cervix uteri NHL	Breast Cervix uteri Prostate
<b>Prevalence*</b>			
5-year prevalent cases	16 630	26 988	43 618



## Top 5 most frequent cancers\*\*


**Males**



Rank	Cancer site	Number of cases	Percent
1st	Prostate	2 050	25.7%
2nd	Kaposi sarcoma	797	10.0%
3rd	NHL	748	9.4%
4th	Liver	727	9.1%
5th	Colorectum	482	6.0%
-	Others	3 182	39.8%

Number of new cases in 2022, males, all ages


**Females**



Rank	Cancer site	Number of cases	Percent
1st	Breast	4 207	36.3%
2nd	Cervix uteri	2 525	21.8%
3rd	NHL	732	6.3%
4th	Ovary	490	4.2%
5th	Colorectum	434	3.7%
-	Others	3 190	27.6%

Number of new cases in 2022, females, all ages

**Both sexes**



Rank	Cancer site	Number of cases	Percent
1st	Breast	4 207	21.5%
2nd	Cervix uteri	2 525	12.9%
3rd	Prostate	2 050	10.5%
4th	NHL	1 480	7.6%
5th	Kaposi sarcoma	1 148	5.9%
-	Others	8 154	41.7%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	4 207	1	21.5	5.1	2 285	1	17.9	3.0	10 255	23.5
Cervix uteri	2 525	2	12.9	3.7	1 837	2	14.4	2.9	5 839	13.4
Prostate	2 050	3	10.5	4.7	1 131	3	8.8	2.5	3 895	8.9
NHL	1 480	4	7.6	0.79	834	5	6.5	0.50	3 818	8.8
Kaposi sarcoma	1 148	5	5.9	0.65	696	6	5.4	0.38	2 545	5.8
Liver	972	6	5.0	0.61	910	4	7.1	0.61	1 582	3.6
Colorectum	916	7	4.7	0.72	608	7	4.8	0.49	2 063	4.7
Ovary	490	8	2.5	0.65	406	8	3.2	0.64	1 132	2.6
Stomach	477	9	2.4	0.38	395	9	3.1	0.33	792	1.8
Lung	393	10	2.0	0.35	366	10	2.9	0.34	582	1.3
Nasopharynx	364	11	1.9	0.24	263	12	2.1	0.20	887	2.0
Leukaemia	362	12	1.9	0.19	286	11	2.2	0.17	880	2.0
Lip, oral cavity	237	13	1.2	0.20	160	14	1.3	0.15	535	1.2
Salivary glands	205	14	1.0	0.14	145	16	1.1	0.13	500	1.1
Corpus uteri	203	15	1.0	0.37	77	23	0.60	0.15	546	1.3
Pancreas	187	16	0.96	0.16	168	13	1.3	0.15	233	0.53
Bladder	180	17	0.92	0.16	95	20	0.74	0.09	430	0.99
Oropharynx	177	18	0.91	0.14	117	18	0.91	0.11	430	0.99
Kidney	176	19	0.90	0.08	115	19	0.90	0.07	451	1.0
Oesophagus	165	20	0.84	0.14	158	15	1.2	0.13	259	0.59
Hypopharynx	153	21	0.78	0.10	130	17	1.0	0.08	254	0.58
Melanoma	153	21	0.78	0.14	61	24	0.48	0.05	373	0.86
Thyroid	118	23	0.60	0.09	50	25	0.39	0.05	303	0.70
Hodgkin lymphoma	111	24	0.57	0.05	48	26	0.38	0.02	300	0.69
Brain CNS	109	25	0.56	0.05	87	22	0.68	0.04	315	0.72
Multiple myeloma	105	26	0.54	0.10	94	21	0.73	0.08	239	0.55
Vulva	59	27	0.30	0.10	32	27	0.25	0.04	135	0.31
Vagina	47	28	0.24	0.07	30	28	0.23	0.04	105	0.24
Larynx	38	29	0.19	0.04	26	29	0.20	0.03	92	0.21
Testis	37	30	0.19	0.03	14	31	0.11	0.01	103	0.24
Gallbladder	26	31	0.13	0.02	22	30	0.17	0.02	45	0.10
Penis	9	32	0.05	0.01	5	33	0.04	0.01	23	0.05
<b>All cancers</b>	<b>19 564</b>	-	-	<b>13.1</b>	<b>12 798</b>	-	-	<b>9.4</b>	<b>43 618</b>	-
<b>All cancers excl. NMSC</b>	<b>19 260</b>	-	-	<b>12.9</b>	<b>12 686</b>	-	-	<b>9.3</b>	<b>42 802</b>	-

Data source and methods

Incidence



Country-specific data source: No data  
 Method: No data: the rates are those of neighbouring countries or registries in the same area

Mortality

Country-specific data source: No data  
 Method: Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

